A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872

BACKGROUND. Src signaling is markedly upregulated at the invasive glioblastoma (GBM) front following bevacizumab administration. The Src family kinase inhibitor, dasatinib, can effectively block bevacizumab-induced glioma invasion in preclinical models. We hypothesized that combining bevacizumab wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Galanis, Evanthia, Anderson, S. Keith, Twohy, Erin L., Carrero, Xiomara W., Dixon, Jesse G., Tran, David Dinh, Jeyapalan, Suriya A., Anderson, Daniel M., Kaufmann, Timothy J., Feathers, Ryan W., Giannini, Caterina, Buckner, Jan C., Anastasiadis, Panos Z., Schiff, David
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788934/
https://ncbi.nlm.nih.gov/pubmed/31290996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32340
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados